미국의 외상성 뇌손상 바이오마커 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 샘플 유형별, 용도별, 최종 용도별, 부문 예측(2025-2033년)

Market Size & Trends:

The U.S. traumatic brain injury biomarkers market size was estimated at USD 409.60 million in 2024, is projected to reach 1,854.73 million by 2033, and is forecasted to grow at a CAGR of 18.8% from 2025 to 2033. The U.S. traumatic brain injury (TBI) biomarkers market is expanding significantly due to increasing demand for pediatric TBI diagnosis, growing awareness and funding related to brain injury, and accelerating collaboration between academic institutions and industry.

TBI refers to an unintentional impact to the head that can lead to outcomes ranging from mild impairment to severe neurological damage or even death. According to a report by the Brain Injury Association America, 2025, the U.S. reported approximately 11.4 million individuals over the age of 40 who experienced a traumatic brain injury (TBI) resulting in loss of consciousness are currently living with a disability. In addition, around 2.9 million TBI-related emergency department visits are reported each year, indicating the significant healthcare burden associated with brain injuries.

Children and adolescents are particularly vulnerable to TBIs from falls, sports injuries, and accidents, yet symptoms can be subtle or delayed. Every year in the U.S., pediatric TBI leads to an estimated 500,000 emergency department visits. While children have a lower overall mortality rate, accounting for about 5% of all TBI-related deaths, the broader impact is more evident when considering years of life lost and years lived with disability. These long-term effects are notably greater in children than in adults, with the serious and lasting burden pediatric TBI poses on public health and quality of life. Pediatric care providers are increasingly turning to biomarker diagnostics to make safer and faster decisions, especially to reduce unnecessary radiation exposure from CT scans.

Blood-based biomarkers offer a non-invasive, objective method to assess injury risk and severity in young patients. A collaborative study conducted in June 2024, by renowned hospitals in Switzerland and Spain, discovered potential blood biomarkers that could significantly improve the diagnosis and management of mild traumatic brain injury (mTBI) in children. This multi-center research, involving ABCDx, the University of Geneva, and Vall d'Hebron Hospital, highlighted the potential of these blood biomarkers to accurately differentiate children with intracranial injuries (ICI) from those without. This reduced unnecessary CT scans and shorter hospital observation periods, improving efficiency in pediatric mTBI care.

Strong collaboration between research universities, biotech companies, and healthcare providers is advancing biomarker validation and commercialization. Institutions are working with biotech and diagnostics companies to translate laboratory discoveries into clinical tests. A new clinical trial holds significant promise for advancing the diagnosis and treatment of TBI. Focused on evaluating innovative diagnostic tools or therapeutic approaches, this trial could pave the way for more effective and timely interventions, potentially transforming patient outcomes in acute and long-term TBI management. These partnerships help accelerate clinical trials, FDA submissions, and market entry. In addition, shared data resources and biobanks support longitudinal studies that strengthen biomarker credibility. The U.S. ecosystem's ability to foster innovation through public-private-academic collaboration is a major competitive advantage in expanding the TBI biomarker market.

A convergence of medical, social, and institutional factors drives rising funding for TBI biomarkers in the U.S. market. Growing public awareness of TBIs' long-term consequences, particularly in sports and military populations, has amplified demand for more accurate and timely diagnostic tools. Traditional imaging often falls short in detecting mild or early-stage injuries, creating a critical need for biomarker-based solutions to provide objective, rapid, and non-invasive assessments. In February 2024, government agencies such as the Congressionally Directed Medical Research Programs (CDMRP) and the U.S. Army Medical Research and Development Command (USAMRDC) have increased investments in initiatives like the Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP). These efforts aim to advance early detection, treatment, and prevention strategies, while also addressing the psychological effects of TBI. Coupled with growing commercialization potential and venture capital interest, this influx of funding is accelerating innovation and reshaping the TBI biomarker landscape in the United States.

U.S. Traumatic Brain Injury Biomarkers Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented U.S. traumatic brain injury biomarkers market report based on type, sample type, application, and end use:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Protein Biomarkers
• Genetic Biomarkers
• Metabolomic Biomarkers
• Sample Type Outlook (Revenue, USD Million, 2021 - 2033)
• Blood-based
• Cerebrospinal fluid (CSF)-based
• Urine-based
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Diagnosis
• Prognosis
• Monitoring treatment response
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Diagnostic Laboratories
• Research Institutes

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Sample Type
  • 1.2.3. Application
  • 1.2.4. End user
  • 1.2.5. Country scope
  • 1.2.6. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Sample type outlook
  • 2.2.3. Application outlook
  • 2.2.4. End use outlook
  • 2.2.5. Country outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Traumatic Brain Injury Biomarkers Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Traumatic Brain Injury Biomarkers Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. U.S. Traumatic Brain Injury Biomarkers Market: Type Estimates & Trend Analysis

• 4.1. Type Market Share, 2024 & 2033
• 4.2. Segment Dashboard
• 4.3. U.S. Traumatic Brain Injury Biomarkers Market: Type Movement Analysis
• 4.4. U.S. Traumatic Brain Injury Biomarkers Market Size & Trend Analysis, by type, 2021 to 2033 (USD Million)
• 4.5. U.S. Traumatic Brain Injury Biomarkers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Protein biomarkers
  • 4.6.1. Protein biomarkers Market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.7. Genetic biomarkers
  • 4.7.1. Genetic biomarkers Market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.8. Metabolomic biomarkers
  • 4.8.1. Metabolomic biomarkers Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Traumatic Brain Injury Biomarkers Market: Sample type Estimates & Trend Analysis

• 5.1. Sample type Market Share, 2024 & 2033
• 5.2. Segment Dashboard
• 5.3. U.S. Traumatic Brain Injury Biomarkers Market by Sample type Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Blood-based
  • 5.5.1. Blood-based Market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.6. Cerebrospinal fluid (CSF)-based
  • 5.6.1. Cerebrospinal fluid (CSF)-based Market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.7. Urine-based
  • 5.7.1. Urine-based Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Traumatic Brain Injury Biomarkers Market: Application Estimates & Trend Analysis

• 6.1. Application Market Share, 2024 & 2033
• 6.2. Segment Dashboard
• 6.3. U.S. Traumatic Brain Injury Biomarkers Market by Application Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Diagnosis
  • 6.5.1. Diagnosis Market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Prognosis
  • 6.6.1. Prognosis Market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.7. Monitoring treatment response
  • 6.7.1. Monitoring treatment response, Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Traumatic Brain Injury Biomarkers Market: End use Estimates & Trend Analysis

• 7.1. End Use Market Share, 2024 & 2033
• 7.2. Segment Dashboard
• 7.3. U.S. Traumatic Brain Injury Biomarkers Market by End use Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 7.5. Hospitals & Clinics
  • 7.5.1. Hospitals & Clinics Market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.6. Diagnostic Laboratories
  • 7.6.1. Diagnostic Laboratories Market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.7. Research Institutes
  • 7.7.1. Research Institutes Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Traumatic Brain Injury Biomarkers Market: Country Estimates & Trend Analysis

• 8.1. Country Market Share Analysis, 2024 & 2033
• 8.2. Country Market Dashboard
• 8.3. U.S. Country Market Snapshot
• 8.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 8.5. U.S.
  • 8.5.1. Key country dynamics
  • 8.5.2. Regulatory framework/Reimbursement
  • 8.5.3. Competitive scenario
  • 8.5.4. U.S. market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2024
  • 9.3.4. Quanterix.
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Services benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Banyan Biomarkers, Inc.
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Services benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Abbott
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Services benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. GE Healthcare.
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Services benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Thermo Fisher Scientific Inc.
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Services benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Immunarray.
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Services benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Oculogica
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Services benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. NeuroTrauma Sciences, LLC
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Services benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. BRAINBox Solutions, Inc.
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Services benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Myriad Genetics, Inc.
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Services benchmarking
    • 9.3.13.4. Strategic initiatives
  • 9.3.14. Abcam Limited
    • 9.3.14.1. Company overview
    • 9.3.14.2. Financial performance
    • 9.3.14.3. Services benchmarking
    • 9.3.14.4. Strategic initiatives